Prevention and control of emesis is of paramount importance in the treatment of cancer patients otherwise may ground in serious health concerns. hence our research is focused and oriented towards targeting cinv. the parenteral and enteral routes mentioned has several disadvantages such as poor patient compliance, painful in case of injections, not feasible for self-administration, high cost, poor absorption, poor bioavailability, lack of programmability. administration of higher doses due to poor absorption results in many side effects ranging from less serious to more serious viz., fever, hearing loss, constipation, ringing ears, severe stomach pain, allergic reaction marked by swelling face or throat, cns depression, disturbed cardiac conduction. on the onset, we have oriented our research towards the designing of novel and alternative approach for addressing the emesis by developing the novel wearable bioinspired microneedle based trans-epidermal drug delivery device which imitate the same mechanism of pharmacological actions exhibited by current mode of administration and doses of drugs used for treatment of emesis without any notified side-effects and better patient compliance. the device is convenient, save time, and improve self-image. consumers do not like to think of themselves as patients and want to minimize the energy focused on their disease. so, we believe with wearable we are transforming how medicine is delivered and how people achieve their health goals through the convergence of optimized drug delivery, embedded sensor technology to monitor compliance, connected and personalized behavioral support. in order to determine the biosafety and amount of drug reaching the systemic circulation by developed microneedle and initial prototype device has to undergo stringent testing both in vitro and in vivo. results from in vitro studies are sometimes hard to extrapolate for in vivo system. for this reason, the use of animal models is essential to judge clinical suitability of novel drug delivery method intended to be used to deliver antiemetic, prior to clinical use in humans. the promising scope of microneedles with sparse dose requirement reduces the major cost incurred. painless trans-epidermal drug delivery with better patient compliance and behavioral support featured by wearable reduces the dependencies on trained nursing staff enabling users to self-administer and monitor the drug delivery. this tremendously curtails the cost incurred by patient on daily supportive/nursing care services. possible mass production, low cost manufacturing (as the process of fabrication is influenced from std ic industries), simple storage, handling and distribution may promote use of microneedles based wearable drug delivery device in mainstream healthcare.